Plasma extracellular vesicle proteomics nominates candidate biomarkers of 177Lu-PSMA-617 outcomes in metastatic prostate cancer patients.

Saved in:
Bibliographic Details
Title: Plasma extracellular vesicle proteomics nominates candidate biomarkers of 177Lu-PSMA-617 outcomes in metastatic prostate cancer patients.
Authors: Arafa AT; Department of Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA., Boytim E; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA., Ludwig ML; Department of Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA., Kollitz L; Nuclear Medicine Division, Department of Radiology, University of Minnesota Medical School, Minneapolis, MN 55455, USA., Yang T; Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, MN, USA., Storey KM; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA., Bloom S; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA., Jha G; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA., Okazaki I; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA., Ryan CJ; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Zorko NA; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA., Steinberger D; Nuclear Medicine Division, Department of Radiology, University of Minnesota Medical School, Minneapolis, MN 55455, USA., Cayci Z; Nuclear Medicine Division, Department of Radiology, University of Minnesota Medical School, Minneapolis, MN 55455, USA., Zhao Y; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA., Villalta PW; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA; Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN 55455, USA., Dehm SM; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA; Department of Urology, University of Minnesota, Minneapolis, MN 55455, USA., Hwang JH; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA., Drake JM; Department of Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA; Department of Urology, University of Minnesota, Minneapolis, MN 55455, USA; Astrin Biosciences, Saint Paul, MN 55114, USA. Electronic address: jdrake@umn.edu., Antonarakis ES; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: anton401@umn.edu.
Source: Cell reports. Medicine [Cell Rep Med] 2026 May 19; Vol. 7 (5), pp. 102764. Date of Electronic Publication: 2026 Apr 20.
Publication Type: Journal Article
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-3791
DOI:10.1016/j.xcrm.2026.102764